42.09
price up icon0.84%   0.35
after-market After Hours: 42.09
loading
Agios Pharmaceuticals Inc stock is traded at $42.09, with a volume of 324.19K. It is up +0.84% in the last 24 hours and up +11.14% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$41.74
Open:
$41.92
24h Volume:
324.19K
Relative Volume:
0.44
Market Cap:
$2.45B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.7051
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+1.37%
1M Performance:
+11.14%
6M Performance:
+48.36%
1Y Performance:
-5.05%
1-Day Range:
Value
$41.27
$42.11
1-Week Range:
Value
$41.24
$43.69
52-Week Range:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Name
Agios Pharmaceuticals Inc
Name
Phone
617-649-8600
Name
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
488
Name
Twitter
@AgiosPharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
42.09 2.52B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.63 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.00 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.69 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.18 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.03 34.68B 4.56B -176.77M 225.30M -1.7177

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-24-25 Initiated H.C. Wainwright Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-10-24 Resumed Raymond James Outperform
Sep-27-24 Downgrade Leerink Partners Outperform → Market Perform
Feb-08-24 Initiated Cantor Fitzgerald Overweight
Feb-03-23 Initiated Piper Sandler Overweight
Nov-17-22 Upgrade Goldman Sell → Neutral
Jul-27-22 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-03-21 Initiated BofA Securities Buy
Jul-30-21 Downgrade Goldman Neutral → Sell
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-10-21 Initiated H.C. Wainwright Buy
Mar-01-21 Downgrade JP Morgan Overweight → Neutral
Mar-01-21 Upgrade SVB Leerink Mkt Perform → Outperform
Feb-26-21 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-22-20 Upgrade Barclays Equal Weight → Overweight
Mar-04-20 Initiated Barclays Equal Weight
Nov-26-19 Initiated Cantor Fitzgerald Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
May-23-19 Resumed Goldman Neutral
Feb-15-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-25-18 Initiated Leerink Partners Mkt Perform
May-23-18 Initiated Citigroup Buy
Apr-11-18 Reiterated Credit Suisse Outperform
Feb-15-18 Reiterated Needham Buy
Feb-15-18 Reiterated SunTrust Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Aug-10-17 Reiterated Needham Buy
Aug-08-17 Reiterated SunTrust Buy
Aug-02-17 Upgrade Leerink Partners Mkt Perform → Outperform
Jun-26-17 Downgrade Janney Buy → Neutral
Jan-17-17 Upgrade Oppenheimer Perform → Outperform
Oct-24-16 Initiated Needham Buy
Jun-13-16 Upgrade JP Morgan Neutral → Overweight
May-18-16 Reiterated SunTrust Buy
View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

pulisher
Oct 23, 2025

Candlestick signals on Agios Pharmaceuticals Inc. stock todayGDP Growth & Real-Time Buy Zone Alerts - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Can Agios Pharmaceuticals Inc. stock reach $100 price target2025 Growth vs Value & AI Enhanced Trading Signals - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Can Agios Pharmaceuticals Inc. stock deliver sustainable ROEQuarterly Profit Review & Low Risk High Win Rate Stock Picks - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Is Agios Pharmaceuticals Inc. (8AP) stock considered safe havenM&A Rumor & Safe Entry Zone Identification - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

How Agios Pharmaceuticals Inc. stock reacts to bond yieldsWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

Relative strength of Agios Pharmaceuticals Inc. in sector analysisMarket Movement Recap & Community Supported Trade Ideas - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Agios Pharmaceuticals Inc. see short term momentumMarket Activity Recap & Free Community Consensus Stock Picks - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Has Agios Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Short Interest & Weekly Stock Performance Updates - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsDividend Hike & Smart Money Movement Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesWatch List & Community Verified Swing Trade Signals - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Agios Pharmaceuticals Inc. (8AP) stock outperform Dow JonesIPO Watch & Free Technical Pattern Based Buy Signals - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: 9.42% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews

Oct 21, 2025
pulisher
Oct 20, 2025

Will Agios Pharmaceuticals Inc. outperform the market2025 Biggest Moves & Verified Entry Point Signals - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Why Agios Pharmaceuticals Inc. (8AP) stock gets analyst attentionPortfolio Value Summary & High Yield Stock Recommendations - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

What analysts say about Agios Pharmaceuticals Inc stockStock Market Trends & Free Gain Edge With Data - earlytimes.in

Oct 20, 2025
pulisher
Oct 20, 2025

Published on: 2025-10-20 16:50:40 - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Dividend Watch: Is Agios Pharmaceuticals Inc. (8AP) stock considered safe havenMarket Volume Summary & Weekly Watchlist of Top Performers - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

H.C. Wainwright reiterates Buy rating on Agios Pharma stock amid positive EMA opinion - Investing.com Canada

Oct 20, 2025
pulisher
Oct 20, 2025

Is Agios Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Movers & Daily Stock Trend Reports - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia - BioSpace

Oct 20, 2025
pulisher
Oct 19, 2025

Analyzing recovery setups for Agios Pharmaceuticals Inc. investorsWeekly Gains Summary & Safe Entry Point Identification - newser.com

Oct 19, 2025
pulisher
Oct 18, 2025

Risk Check: Can Agios Pharmaceuticals Inc. stock rebound after recent weaknessTrade Analysis Summary & Expert Curated Trade Setup Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - WV News

Oct 18, 2025
pulisher
Oct 18, 2025

Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease - Yahoo Finance

Oct 18, 2025
pulisher
Oct 18, 2025

Will Agios Pharmaceuticals Inc. stock maintain growth storyJuly 2025 Action & Weekly Setup with ROI Potential - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Agios Pharmaceuticals Inc. stock benefit from commodity prices2025 Earnings Surprises & Fast Gaining Stock Strategy Reports - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

How Agios Pharmaceuticals Inc. stock performs during Fed tightening cyclesJuly 2025 Weekly Recap & Technical Pattern Based Signals - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Guidance Update: How Agios Pharmaceuticals Inc. stock performs during Fed tightening cyclesSwing Trade & Real-Time Stock Entry Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

CHMP backs Agios’ PYRUKYND for thalassemia treatment in Europe By Investing.com - Investing.com Canada

Oct 17, 2025
pulisher
Oct 17, 2025

Chart Watch: Can Agios Pharmaceuticals Inc. stock rebound after recent weaknessPortfolio Gains Report & Fast Momentum Entry Tips - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

European regulators back Agios’ thalassemia treatment - Investing.com

Oct 17, 2025
pulisher
Oct 17, 2025

CHMP backs Agios’ PYRUKYND for thalassemia treatment in Europe - Investing.com

Oct 17, 2025
pulisher
Oct 17, 2025

Agios Pharmaceuticals Says EU Panel Gave Positive Opinion For Pyrukynd For Adults With Thalassemia - MarketScreener

Oct 17, 2025
pulisher
Oct 17, 2025

Agios Pharmaceuticals (AGIO) Gains Positive CHMP Opinion for PYR - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Agios Pharmaceuticals Receives Positive CHMP Opinion for PYRUKYND® Indication in Thalassemia Treatment - Quiver Quantitative

Oct 17, 2025
pulisher
Oct 17, 2025

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia - The Manila Times

Oct 17, 2025
pulisher
Oct 17, 2025

European regulators back Agios’ thalassemia treatment By Investing.com - Investing.com UK

Oct 17, 2025
pulisher
Oct 17, 2025

CHMP Issues Positive Opinion for PYRUKYND — Agios advances treatment for adults with thalassemia - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

How Positive CHMP Opinion and European Deal for PYRUKYND May Impact Agios Pharmaceuticals (AGIO) Investors - Sahm

Oct 17, 2025
pulisher
Oct 16, 2025

Why (AGIO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com

Oct 16, 2025
pulisher
Oct 16, 2025

Agios Pharmaceuticals to Host Conference Call for Q3 2025 Financial Results and Business Highlights - Quiver Quantitative

Oct 16, 2025
pulisher
Oct 16, 2025

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET - The Manila Times

Oct 16, 2025
pulisher
Oct 15, 2025

What drives Agios Pharmaceuticals Inc stock priceGrowth vs. Value Investing & Free Wealth Planning Blueprints - earlytimes.in

Oct 15, 2025
pulisher
Oct 14, 2025

Agios Q2 2025 slides: PYRUKYND sales jump 45% as thalassemia approval nears - Investing.com Australia

Oct 14, 2025

Agios Pharmaceuticals Inc Stock (AGIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.85
price up icon 0.03%
$89.31
price up icon 1.42%
$29.87
price down icon 0.17%
$104.75
price down icon 1.39%
$160.12
price down icon 0.17%
biotechnology ONC
$310.03
price down icon 1.12%
Cap:     |  Volume (24h):